The Indonesian Supreme Court has rejected an appeal filed by the country’s antitrust agency to rehear a case brought against Pfizer. The regulator, KPPU, had found in 2010 that Pfizer, its subsidiaries, and Dexa Medica (a local company) were abusing their dominant positions in the market for antihypertensive products. The KPPU said that these companies were overcharging local customers 14.6 times the price that the World Health Organization (“WHO”) paid for Pfizer’s antihypertensive medication, which should have reasonably been around 2.5 times the price offered to the WHO. The Pfizer companies were fined IDR 25 billion; Dexa Medica was fined IDR 20 billion.
Featured News
Trump’s Defamation Case Against New York Times Advances in Federal Court
Nov 19, 2026 by
CPI
Musk’s xAI Faces Skeptical US Judges Over California AI Disclosure Law
Nov 19, 2026 by
CPI
Italy Ends Vorwerk Antitrust Probe After Consumer Compensation Deal
Nov 19, 2026 by
CPI
Canada Wins Court Order to Advance Gap, Old Navy Advertising Probe
Nov 19, 2026 by
CPI
Russia Orders Major Retailers to Disclose Food Pricing Data in Antitrust Review
Nov 19, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Labor Market Collusion
Nov 19, 2026 by
CPI
From Price-Fixing to Wage-Fixing: Are Labor Markets the Next Frontier of Public and Private Competition Law Enforcement?
Nov 19, 2026 by
Giulia Rurali & Carsten Krüger
Damage Estimation and Labor Market Collusion
Nov 19, 2026 by
Louis D. Pape
Recent Developments of Labor Market Collusion in the EU: The Dialogue Between Delivery Hero and Tondela
Nov 19, 2026 by
Catarina Vieira Peres & Rita Ferreira Gomes
Enforcement in Labor Collusion and Monopsony: Trends and Challenges
Nov 19, 2026 by
Leyla Karakas & Anna Meyendorff